caa a22 4500 606236309 CHVBK 20210128101247.0 cr unu---uuuuu 210128e20150801xx s 000 0 eng 10.1007/s11010-015-2429-8 doi (NATIONALLICENCE)springer-10.1007/s11010-015-2429-8 Baicalein inhibits prostate cancer cell growth and metastasis via the caveolin-1/AKT/mTOR pathway [Elektronische Daten] [Zhaoxin Guo, Xiaolin Hu, Zhaoquan Xing, Rui Xing, Renguang Lv, Xiangyu Cheng, Jing Su, Zunlin Zhou, Zhonghua Xu, Sten Nilsson, Zhaoxu Liu] Prostate cancer (PCa) is lethal type of genitourinary cancer due to its high morbidity and gradual resistance to androgen deprivation therapy. Accumulating evidence has recently suggested that the daily intake of flavonoids is negatively correlated with the risk of cancer. In this study, we aimed to investigate the potential effects of baicalein on androgen-independent PCa cells and the underlying mechanisms through which baicalein exerts its actions. Cell viability and flow cytometric apoptosis assays indicated that baicalein potently suppressed the growth and induced the apoptosis of DU145 and PC-3 cells in a time- and dose-dependent manner. Consistently, the inhibitory effects of baicalein on migration and invasion were also observed in vitro. Mechanistically, we found that baicalein can suppress caveolin-1 and the phosphorylation of AKT and mTOR in a time- and dose-dependent manner. Moreover, the inhibition of the activation of AKT with LY294002 significantly promoted the apoptosis and metastasis induced by baicalein. In conclusion, these findings suggested that baicalein can induce apoptosis and inhibit metastasis of androgen-independent PCa cells through inhibition of the caveolin-1/AKT/mTOR pathway, which implies that baicalein may be a potential therapeutic agent for the treatment of androgen-independent prostate cancer patients. The Author(s), 2015 Baicalein nationallicence Anti-cancer activity nationallicence Androgen-independent prostate cancer nationallicence Metastasis nationallicence Caveolin-1 nationallicence Guo Zhaoxin Department of Urology, Qilu Hospital of Shandong University, 250012, Jinan, Shandong, China aut Hu Xiaolin Department of Endocrinology, Jinan Central Hospital, Shandong University, 250013, Jinan, Shandong, China aut Xing Zhaoquan Department of Urology, Qilu Hospital of Shandong University, 250012, Jinan, Shandong, China aut Xing Rui Department of Urology, Linyi County People's Hospital, 251500, Dezhou, Shandong, China aut Lv Renguang Department of Urology, Jinan Iron and Steel General Hospital, 250000, Jinan, Shandong, China aut Cheng Xiangyu Department of Urology, Qilu Hospital of Shandong University, 250012, Jinan, Shandong, China aut Su Jing School of Nursing, Shandong University, No. 107 Wenhua Xi Road, 250012, Jinan, Shandong, China aut Zhou Zunlin Department of Urology, Qilu Hospital of Shandong University, 250012, Jinan, Shandong, China aut Xu Zhonghua Department of Urology, Qilu Hospital of Shandong University, 250012, Jinan, Shandong, China aut Nilsson Sten Department of Oncology and Pathology, Karolinska Institutet, 17177, Stockholm, Sweden aut Liu Zhaoxu Department of Urology, Qilu Hospital of Shandong University, 250012, Jinan, Shandong, China aut Molecular and Cellular Biochemistry Springer US; http://www.springer-ny.com 406/1-2(2015-08-01), 111-119 0300-8177 406:1-2<111 2015 406 11010 https://doi.org/10.1007/s11010-015-2429-8 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s11010-015-2429-8 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Guo Zhaoxin Department of Urology, Qilu Hospital of Shandong University, 250012, Jinan, Shandong, China aut NATIONALLICENCE 700 1- Hu Xiaolin Department of Endocrinology, Jinan Central Hospital, Shandong University, 250013, Jinan, Shandong, China aut NATIONALLICENCE 700 1- Xing Zhaoquan Department of Urology, Qilu Hospital of Shandong University, 250012, Jinan, Shandong, China aut NATIONALLICENCE 700 1- Xing Rui Department of Urology, Linyi County People's Hospital, 251500, Dezhou, Shandong, China aut NATIONALLICENCE 700 1- Lv Renguang Department of Urology, Jinan Iron and Steel General Hospital, 250000, Jinan, Shandong, China aut NATIONALLICENCE 700 1- Cheng Xiangyu Department of Urology, Qilu Hospital of Shandong University, 250012, Jinan, Shandong, China aut NATIONALLICENCE 700 1- Su Jing School of Nursing, Shandong University, No. 107 Wenhua Xi Road, 250012, Jinan, Shandong, China aut NATIONALLICENCE 700 1- Zhou Zunlin Department of Urology, Qilu Hospital of Shandong University, 250012, Jinan, Shandong, China aut NATIONALLICENCE 700 1- Xu Zhonghua Department of Urology, Qilu Hospital of Shandong University, 250012, Jinan, Shandong, China aut NATIONALLICENCE 700 1- Nilsson Sten Department of Oncology and Pathology, Karolinska Institutet, 17177, Stockholm, Sweden aut NATIONALLICENCE 700 1- Liu Zhaoxu Department of Urology, Qilu Hospital of Shandong University, 250012, Jinan, Shandong, China aut NATIONALLICENCE 773 0- Molecular and Cellular Biochemistry Springer US; http://www.springer-ny.com 406/1-2(2015-08-01), 111-119 0300-8177 406:1-2<111 2015 406 11010